Restylane Eyelight Lidocaine 1x 0,5 ml

Restylane Eyelight Lidocaine features 20 mg/mL of cross-linked hyaluronic acid, stabilised using Galderma’s NASHA™ technology. This non-animal, biofermented HA offers a tight, monophasic gel structure with a relatively high G’ for projection while minimising swelling in the delicate periorbital zone.

The formulation includes 0.3% lidocaine for patient comfort. NASHA™ cross-linking creates a dense, cohesive gel that resists deformation under the thin orbital skin, ensuring even distribution without lumping or Tyndall effect. Importantly, the low water-uptake profile reduces post-injection oedema—a crucial benefit for tear trough use, where overcorrection can cause unnatural bulging.

Because the HA is highly purified and sourced by bacterial fermentation, there's no need for allergy testing. The gel is fully reversible with hyaluronidase, offering clinicians peace of mind when treating a high-risk vascular area. With its carefully tuned viscosity and particle size, Restylane Eyelight achieves subtle yet effective correction with small injection volumes. sample

Restylane Eyelight Lidocaine is designed specifically for the correction of infraorbital hollowing, commonly called tear trough deformity. The under-eye area is one of the most technically demanding regions to treat, given its thin skin, superficial vessels, and tendency to show contour irregularities.

This filler is suitable for patients with mild-to-moderate volume loss under the eyes, including those with genetically deep tear troughs or age-related fat pad atrophy. It delivers natural-looking results that blend seamlessly with adjacent tissues. Unlike less cohesive gels or overly hydrophilic fillers, Eyelight minimises swelling risk—a common complication in this area.

Compared to alternative treatments like autologous fat transfer, Eyelight offers a predictable, minimally invasive solution with immediate results and far less downtime. Unlike biostimulatory fillers such as PLLA or CaHA, which are generally avoided near the orbit due to nodule risk, this HA gel remains smooth and can be dissolved if needed. s

Each Restylane Eyelight Lidocaine box contains:
• 1 × 0.5 mL sterile glass syringe with Luer-Lock tip, pre-filled with NASHA™ cross-linked HA
• 1 × 30 G ½″ sterile needle optimised for linear threading in the tear trough
• Multilingual instructions for use detailing contraindications, precautions and emergency reversal with hyaluronidase
• 2 peel-off traceability labels to ensure compliance with EU MDR Class III requirements and facilitate patient record-keeping

Packaging is tamper-evident and temperature-stable between 2 and 25 °C. The manufacturer recommends single-use disposal within four hours of opening to maintain sterility and minimise bioburden.

Clinical studies and practitioner experience suggest Restylane Eyelight Lidocaine provides effective tear trough correction for 6–9 months, with variability depending on patient age, metabolism, and injection technique. Its NASHA™ cross-linked structure ensures slow, predictable degradation. While it lacks the extreme longevity of deep volumisers like Restylane Volyme or Lyft in other areas, Eyelight is optimised for the fragile infraorbital zone where overcorrection must be avoided. In practice, most patients achieve noticeable hollowing reduction with a single 0.5 mL session, sometimes followed by a small touch-up at 6 months. Patient satisfaction rates remain high, with minimal swelling, bruising and lump formation compared to older HA formulas. Maintenance typically involves annual or semiannual retreatment, which aligns with the natural aging process while preserving a smooth, rested appearance.

Q1 – Is Restylane Eyelight Lidocaine FDA-approved?A1: No. While many Restylane products hold FDA approval, Eyelight is CE-marked for use in Europe and other regions but not FDA-cleared in the US.

Q2 – How quickly will I see results?A2: Results are visible immediately post-injection. Minor swelling usually resolves in 24–48 hours, revealing the final contour.

Q3 – Can the filler be reversed if needed?A3: Yes. Like all hyaluronic acid gels, Eyelight responds to hyaluronidase, typically dissolving within minutes if overcorrection or complications occur.

Restylane Eyelight Lidocaine is produced by Galderma, a global leader in dermatology founded in 1981 and headquartered in Switzerland. Galderma maintains ISO 13485-certified manufacturing facilities in Sweden and France, with rigorous quality controls meeting EU and global standards for Class III medical devices.

The company’s proprietary NASHA™ technology underpins the entire Restylane family, providing a range of gels tailored for different depths and indications—from fine lines to deep volumisation. Eyelight was developed specifically for the infraorbital zone, addressing unique clinical challenges with a cohesive, low-swelling formula.

Galderma has a long history of innovation in medical aesthetics, dermatology and therapeutic skincare, with ongoing investment in research, clinician education and sustainability. Recent initiatives include reducing packaging waste, adopting renewable energy in production sites, and funding scholarships for injector training globally.

With decades of clinical data and millions of treatments worldwide, Restylane remains one of the most trusted brands in hyaluronic acid dermal fillers. Eyelight continues this legacy, offering a safe, effective and patient-friendly solution for under-eye rejuvenation.